β-ADRENERGIC RECEPTOR BLOCKERS AS A REGULATOR OF T CELL VIABILITY  (IN THE MODEL SYSTEM OF THE JURKAT CELLS)

TAMAR  SHARASHENIDZE; MAIA  ENUKIDZE; MARINE  MACHAVARIANI; NINO  OTARISHVILI; TEA  GABUNIA; TAMAR  SANIKIDZE

doi:10.52340/jecm.2022.06.002

β-ADRENERGIC RECEPTOR BLOCKERS AS A REGULATOR OF T CELL VIABILITY (IN THE MODEL SYSTEM OF THE JURKAT CELLS)

Authors

TAMAR SHARASHENIDZE
MAIA ENUKIDZE
MARINE MACHAVARIANI
NINO OTARISHVILI
TEA GABUNIA
TAMAR SANIKIDZE

DOI:

https://doi.org/10.52340/jecm.2022.06.002

Keywords:

β-blockers, T cells viability, adrenoreceptors

Abstract

Our research aimed to establish the effectiveness of various β-adrenergic receptor blockers in the regulation of T cell proliferation in the model system of the Jurkat cells.Material and Methods. The research was conducted on the human leukemic mature T cells (Jurkat cells) (DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen (Germany)) activated by phytohemagglutinin (PHA). Viability and proliferative activity of intact and PHA-stimulated Jurkat cells under the influence of Nebilet, Egilok, Betalok Zok, and Propranolol were studied with the MTT test. Results. Study results show that β-adrenergic receptors blockers selectively influence the activity of mitochondrial dehydrogenases, and therefore viability in both intact and mitogen-stimulated Jurkat cells. In particular, Nebilet, Betalok Zok, and Propranolol induced a statistically significant decrease of intact Jurkat cells viability by 63%, 20%, and 32%, respectively; Egilok and Betalok Zok (25mg) didn’t statistically significantly affect the PHA- activated Jurkat cells viability. Nebilet, Betalok Zok (50 mg), and Propranolol decreased the viability of the mitogen (PHA) activated Jurkat cells (for PHA dose 20μg/ml) and didn’t affect at a PHA dose of 50μg/ml.

Downloads

Download data is not yet available.

References

Vivek Jain, Jitendra Choudhary, Rahul Pandit. Blood Pressure Target in Acute Brain Injury. Indian J Crit Care Med. 2019 Jun; 23(Suppl 2): S136–S139. DOI: 10.5005/jp-journals-10071-23191.

Wenzel UO, Bode M, Köhl J, Ehmke H.A pathogenic role of complement in arterial hypertension and hypertensive end-organ damage. Am J Physiol Heart Circ Physiol. 2017 Mar 1;312(3):H349-H354. DOI:10.1152/ajpheart.00759.2016. Epub 2016 Dec 16. PMID: 2798666

Tanase DM, Gosav EM, Radu S, Ouatu A, Rezus C, Ciocoiu M, et al. Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker? International Journal of Hypertension, 2019; 2019 3159283. PMID: 31186952. PMCID: PMC6521461. DOI: 10.1155/2019/3159283.

Peeters AC, Netea MG, Janssen MC, Kullberg BJ, Van der Meer JW, et al. Pro-inflammatory cytokines in patients with essential hypertension. Eur J Clin Invest. 2001;31(1):31-6. PMID: 11168436. DOI: 10.1046/j.1365-2362.2001. 00743. x.

Norlander AE, Madhur MS, Harrison DG. The immunology of hypertension. J. Exp. Med. 2018; 215,2:21–33. PMID: 29247045. PMCID: PMC5748862. DOI: 10.1084/jem.20171773.

Youn, JC, Yu HT, Lim BJ, Koh MJ, Lee J, Chang DY, et al. Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension. Hypertension. 2013; 62:126–133. PMID: 23716586 DOI: 10.1161/HYPERTENSIONAHA.113.00689.

Basu R, Pathak S., Goyal J, Chaudhry R, Goel, RB, Barwal A. Use of a novel hemoadsorption device for cytokine removal as adjuvant therapy in a patient with septic shock with multi-organ dysfunction: A case study. Indian J Crit Care Med. 2014; 18(12): 822–824. PMID: 25538418. PMCID: PMC4271283. DOI: 10.4103/0972-5229.146321.

Nguyen, H, Chiasson VL, Chatterjee P, Kopriva SE, Young KJ, Mitchell BM. Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension. Cardiovasc. Res. 2013; 97:696–704. PMID: 23263331. PMCID: PMC3583258. DOI: 10.1093/cvr/cvs422.

Kin NW, Sanders VM. It takes nerve to tell T and B cells what to do. Leukoc. Biol. 2006;79: 1093–1104. PMID: 16531560. DOI: 10.1189/jlb.1105625.

Kohm AP, Sanders VM. Norepinephrine and β2-Adrenergic Receptor Stimulation Regulate CD4+ T and B Lymphocyte Function in Vitro and in Vivo, Pharmacol Rev. 2001; 53(4): 487–525. PMID: 11734616.

Du Y, Li X., Yu H., Yan l., Lau WB., Zhang S., et al. Activation of T Lymphocytes as a Novel Mechanism in Beta1-Adrenergic Receptor Autoantibody-Induced Cardiac Remodeling. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-019-06856-2

Fan X, Wang Y. β2 adrenergic receptor on T lymphocytes and its clinical implications. Progress in Natural Science. 2009;19: 17–23. PMID: 20137264.

Krasnikova TL, Kozlova MV, Kalentchuk VU, Suvorov Y, Parfenova EV, Radiukhin VA, et al. Beta-blocker action on lymphocyte proliferative response in essential hypertension. Cor Vasa. 1988;30(2):110-4. PMID: 2899017.

Montminy M. Transcriptional regulation by cyclic AMP. Annu Rev Biochem. 1997; 66:807-22. DOI: 10.1146/annurev.biochem.66.1.807.PMID: 9242925.

Hajighasemi F, Mirshafiey A. In Vitro Sensitivity of Leukemia Cells to Propranolol. J Clin Med Res. 2009;1(3):144-149. PMID: 22493648. PMCID: PMC3318877. DOI: 10.4021/jocmr2009.06.1244.

Silva IVG, de Figueiredo RC, Alves Rios DRA. Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation. Int J Mol Sci. 2019; 20(14): 3458. PMID: 31337127. PMCID: PMC6678872. DOI: 10.3390/ijms20143458.

Gupta S. Wright HM. Nebivolol: A Highly Selective β1-Adrenergic Receptor Blocker That Causes Vasodilation by Increasing Nitric Oxide Cardiovascular Therapeutics. 2008; 26:189–202.PMID: 18786089. DOI: 10.1111/j.1755-5922.2008. 00054.x.

Goodnow CC. Balancing immunity, autoimmunity, and self-tolerance. Ann N Y Acad Sci. 1997;5; 815:55-66. PMID: 9186639. DOI: 10.1111/j.1749-6632. 1997.tb52044.x.

Hajighasemi F, Mirshafiey A. Propranolol effect on proliferation and vascular endothelial growth factor secretion in human immunocompetent cells. Journal of Clinical Immunology and Immunopathology Research, 2009; 2(2):22-27. PMID: 22493648. PMCID: PMC3318877. DOI: 10.4021/jocmr2009.06.1244.

Takemura H, Hatta Sh, Yamada K, Ohsika H. β-adrenergic receptor-mediated calcium mobilization in the human Jurkat T cell line. Life Science. 1995;56,18:1443-1454. PMID: 775280 DOI: 10.1016/0024-3205(95)00107-h.

Hajighasemi F, Mirshafiey A. Regulation of inflammatory cytokines in human immunocompetent cells by propranolol in vitro. European Respiratory Journal, 2016; 48: PA1083; DOI: 10.1183/13993003.congress-2016.PA1083.

Lomsadze GO, Enukidze MG, Machavariani MG, Kioaroidze SA, Gogebashvili NB, Sanikidze TV. β2-adrenergic regulation of T lymphocytes function (in vitro study). Georgian Med News. 2013;(223):60-4. PMID: 24214595

Sharashenidze T, Mamamtavrishvili N, Enukidze M, Machavariani M, Gabunia T, Sanikidze T. Effect of Proportional on cytokine profile in an experimental model of human T Lymphocytes (JURKAT cells) in vitro. Georgian Medical News, 2021, 311):169-172 PMID: 33814413.